Moreover, lower mRNA levels of lL6, TNFα and IL8, the human orthologue to mouse Cxcl1 (Fig. 5g), could be associated with a better prognosis in lung AC patients harboring K‐RAS mutations.39 Taken together, we provide here evidence that ruxolitinib treatment succesfully impairs K‐RAS activity in lung tumors and leads to the establishment of an anti‐inflammatory and antitumorgenic tumor microenviroment. Here, KRAS is linked to neoplasm.